Senores Pharmaceuticals Limited — Investor Meet, 30-07-2025: Analysts/Institutional Investor Meet/Con. Call Updates

Senores Pharmaceuticals delivered a strong Q1FY26: consolidated revenue surged 72%, EBITDA 60%, and PAT 95%. Management foresees robust FY26 with 50% top-line and 100% PAT growth. Regulated markets grew 69% YoY, bolstered by US local manufacturing and a US$23M CDMO/CMO order book. US capacity is set to expand to 2 billion units. Emerging markets revenue increased 32%, aiming for double-digit EBITDA. India's branded generics target ₹50 Cr revenue. The company reported positive operating cash flow, underscoring a confident business outlook.